CN202859206U - Carrier barrier system applied to prevention and treatment of intrauterine adhesion - Google Patents
Carrier barrier system applied to prevention and treatment of intrauterine adhesion Download PDFInfo
- Publication number
- CN202859206U CN202859206U CN 201220218130 CN201220218130U CN202859206U CN 202859206 U CN202859206 U CN 202859206U CN 201220218130 CN201220218130 CN 201220218130 CN 201220218130 U CN201220218130 U CN 201220218130U CN 202859206 U CN202859206 U CN 202859206U
- Authority
- CN
- China
- Prior art keywords
- sacculus
- carrier
- barrier
- carrier barrier
- barrier system
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Images
Landscapes
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Surgical Instruments (AREA)
Abstract
The utility model provides a carrier barrier system applied to prevention and treatment of intrauterine adhesion. The barrier system comprises a cervical conformable plug injection device and a carrier barrier material serving as an injected material, and is characterized in that the cervical conformable plug injection device comprises a nondestructive guide ball head, an endocervical medicine injection hole, a blockage balloon, a dual-cavity catheter and a barrier carrier injection hole which are connected in sequence; a branch balloon injection hole is also formed in the position close to the barrier carrier injection hole in the dual-cavity catheter; the blockage balloon is arranged outside the cervical orifice; and the carrier barrier material is a colloid-shaped human degradable and absorbable material. The barrier system can be used for favorably isolating the uterine cavity, reducing the concentration of adhesion factor and promoting endometrial regeneration and repair.
Description
Technical field
The invention belongs to the suitable type carrier barrier system technical field of using in the control intrauterine adhesion.
Background technology
Intrauterine adhesion be because dilatation and curettage, infect due to basal layer damage and cicatrization, be a kind of commonly encountered diseases, frequently-occurring disease, betide especially easily the intrauterine surgical operation of pregnant relevant disease, sickness rate is 30-40% in this class patient.Although in the Chinese large sample Epidemiological study that does not have relevant sickness rate, nearly 30 years reform and opening-up, the change of people's life idea and life pattern, artificial abortion is high; In addition, painless abortion is extensively carried out, the patient comfortable, lose consciousness fully, painless middle acceptance suction, dilatation and curettage operation, can't perception to the endometrium wound, therefore, intrauterine adhesion is very common in China.Intrauterine adhesion can cause the minimizing of patient's menstrual blood volume, amenorrhea, infertile, have a strong impact on patient's healthy reproduction, has destroyed the harmony, stable of family and society.
At present home and abroad prevention intrauterine adhesion method has a lot, mainly concentrates on mechanical barrier, estrogen element class medicine.The clinical practice effect is undesirable, and particularly for severe adhesion, again adhesion incidence rate of adherence Separation postoperative is more than 60%.The sacculus of at present clinical practice belongs to mechanical barrier, its exist barrier insufficient, can not degraded and absorbed, standing time is short and cause easily the problem such as secondary infection; And need to greatly expand the cervix uteri mouth when existing mechanical barrier is inserted cervix uteri, cause cervix uteri to tear damage, be difficult for recovering the use of the clinical expansion that left unused.Although and the estrogens medicine can impel endometrium regeneration and repair, for severe adhesion patient uterine cavity wound surface large tracts of land scarring, few residual endometrium is difficult to Regeneration and Repair.
In view of this, be necessary to develop a kind of wound surface of can isolating and prevent again Adhesion formation, can carry the tissue adhesion factor again, promote the carrier barrier system that cell regeneration is repaired.We utilize the biomaterial of the colloid that the human body degradable absorbs as carrier, thereby can inject uterine cavity not needing patient's cervix uteri caused under additional injuries, the painless condition, simultaneously because the plasticity of colloid is effective, the shape that can adapt to uterine cavity is fully filled, and sufficient screen effect is provided; Meanwhile, this barrier system can load amnion cell isoreactivity composition, can play to uterine cavity the function of regeneration, reparation.
Summary of the invention
The object of the present invention is to provide a kind of intrauterine perfusion moulding " palace type " carrier barrier system that a kind of degradable absorbs that the invention provides, described barrier system can be realized good uterine cavity isolation, reduces the adhesion factor concentration, promote endometrial regeneration and reparation.
For achieving the above object, the moulding carrier barrier system of intrauterine perfusion that provides a kind of degradable to absorb, described barrier system forms by the suitable type filling injection device of cervix uteri with as the carrier barrier material that is injected into, wherein, the suitable type filling of described cervix uteri injection device is by harmless guiding bulb, medicine injection port in the cervix uteri, stop up sacculus, double channel catheter, the barrier carrier injection port connects to form in turn, position near the barrier carrier injection port on double channel catheter also is provided with sacculus injection bifurcations, the outer tube wall of double channel catheter is provided with the length mark graduation mark, it is characterized in that: be 5-9cm to the length of stopping up sacculus foremost from harmless guiding bulb, make described obstruction sacculus place uterine cavity outside and clogging cervix uteri collar extension; Described carrier barrier material is the material that gluey human body degradable absorbs, and described material is not poisoned human body.
Carrier barrier system of the present invention is provided with valve at the barrier carrier injection port, is provided with check valve at sacculus branch injection port place.
Carrier barrier system of the present invention, the place further arranges the stress test end interface at the barrier carrier injection port, by hydraulic quick coupler Bonding pressure meter, the intrauterine pressure of filling in is monitored in real time.
Carrier barrier system of the present invention, described obstruction sacculus adopt silica gel to make, and its shape can be circular single saccule, the sacculus that is communicated with pair sacculus, capsule shape sacculus or a plurality of connections.Described obstruction sacculus adopts silica gel to make, and the effective thickness of sacculus is 0.3-0.5mm, and maximum is withstand voltage to be 25Kpa.
Carrier barrier system of the present invention, wherein said obstruction sacculus be divided into large in little three specifications, three kinds of specifications are respectively: large size: external diameter is not more than 8.5mm before the inflation, external diameter was not more than 11mm after fluid injection was expanded; Medium size: external diameter is not more than 7.5mm before the inflation, and external diameter was not more than 10mm after fluid injection was expanded; Small size: external diameter is not more than 6mm before the inflation, and external diameter was not more than 8.5mm after fluid injection was expanded.
Carrier barrier system of the present invention is provided with the sacculus liquid injection port at described obstruction sacculus near an end of uterine cavity.
Carrier barrier system of the present invention is characterized in that, also comprises carrier barrier syringe and sacculus syringe.
Carrier barrier system of the present invention, the carrier barrier material that wherein adopts can be selected the composite of one or more compositions in the fibrin gel that polylactic acid (PLA) polymeric material, polyglycolic acid (PGA) polymeric material, polycaprolactone (PCL), natural extracellular matrix components consist of.
Carrier barrier system of the present invention further, loads one or more materials of amnion cell, estrogen, anti-inflammatory drug composition or other competent cell composition at the carrier barrier material that injects.
Description of drawings
Fig. 1 is the overall structure sketch map of control cervical adhesion carrier barrier system when the uterine cavity separating operation;
Fig. 2 A-2D is for stopping up the outline drawing of the various embodiments of sacculus.
The specific embodiment
Accompanying drawing 1 shows the overall structure sketch map of biological barrier system applies of the present invention when the uterine cavity separating operation; Wherein, cartridge syringe 13 is equipped be used to injecting intrauterine carrier barrier material 1, and be used for providing making uterine cavity separate needed safe pressure, the material that employed carrier barrier material adopts the degradable of colloidal to absorb is made, because the material that adopts is colloid, thereby its can be well in uterine cavity " moulding " reach good separation and screen effect to fill intrauterine each space.Front end at double channel catheter 8 has harmless guiding bulb 5, harmless guiding bulb 5 guide catheters enter uterine cavity, front position at conduit has medicine injection port 6 in the uterine cavity, stop up sacculus and be in the position of closing on harmless guiding bulb, in use place outside the uterine cavity, the double channel catheter end is provided with barrier carrier injection port 11, the front of barrier carrier injection port 11 is provided with valve 14 control break-makes, on double channel catheter, also be provided with sacculus injection bifurcations 9 near barrier carrier injection port 11 and the position that is positioned at valve 14 front ends, sacculus injection bifurcations 9 is provided with check valve 10, utilize carrier barrier syringe 13 and sacculus syringe 12 to implement respectively to intrauterine injection with to the injection of sacculus, stop up the preferred medical saline that injects in the sacculus, do not enter in the uterine cavity and the clogging cervix uteri collar extension of energy in order to ensure stopping up sacculus, suitable is controlled at 5-9cm to the length range that stops up sacculus foremost from harmless guiding bulb.
Can select to comprise following several for the material that injects as the carrier barrier:
A), polylactic acid (PLA) polymeric material, it can the oneself destroy (biodegradation), can adapt with human body (biological adaptation), can be hydrolyzed into lactic acid (bio-absorbable) in human body, does not have simultaneously the virose legacy of tool;
B), polyglycolic acid (PGA) polymeric material, all be decomposed into glycolic (bio-absorbable) after three months at implant into body;
C), polycaprolactone, PCL is fine with the biological cell compatibility in vivo, cell can be on its pedestal normal growth, and can be biodegradable into CO2 and H2O;
D), fibrin gel, mainly consisted of by natural extracellular matrix components, have the effective biological activity of good biocompatibility and biodegradability, also have simultaneously three-dimensional porous structure and good plasticity.
Except above-mentioned enumerating, the material of other easy degraded and absorbed and harmless any colloid all can be used for using as the carrier barrier material that injects.
Because the carrier barrier material of the colloid that injects can also be as the carrier of other active substances, thereby in clinical use, further advantageous aspect of the present invention is, will be with amnion cell, estrogen, anti-inflammatory drug composition and/or other cytoactives become to grade to choose as required one or more and load in the selected carrier barrier material and form composite, then together be injected into uterine cavity in by barrier carrier injection port 11 formed composite, flowability based on colloid, the active component that loads can evenly be distributed in the uterine cavity fully, along with the carrier slow degradation, amnion cell isoreactivity material layered coverage uterine cavity Regeneration and Repair, formation meets human body endometrium physiology basal layer and functional layer, plays barrier and regeneration, the function of repairing.
The below further specifies the structure of stopping up sacculus, referring to accompanying drawing 2A-2D, because the carrier barrier material that injects is colloid, it has flowability, thereby need clogging cervix uteri collar extension to prevent and treat its outflow, the means of the obstruction cervix uteri mouth of available technology adopting normally adopt and place intrauterine sacculus to stop up the cervix uteri mouth, such obstruction means cause needing inevitably sacculus is placed a period of time in the uterine cavity after operation finishes, cause unnecessary injury, and place intrauterine sacculus to take this with regard to little in utero space, cause barrier insufficient, effect is undesirable.Because the present invention adopts colloid to belong at present pioneering both at home and abroad as the carrier barrier material, thereby, need and the obstruction sacculus 7 that adopts does not need to enter in the uterine cavity as this particular design, further reduce damage for cervix uteri with this.Described obstruction sacculus adopts silica gel to make, needs according to the clinical uterine cavity internal volume of grasping and pressure tolerance level, the effective thickness of sacculus is designed to 0.3-0.5mm, maximum withstand voltage 25KPa, its profile can be single saccule (referring to accompanying drawing 2A), selectable shape comprises two sacculus (referring to accompanying drawing 2B) of connection, capsule shape sacculus (referring to accompanying drawing 2C), the perhaps such version of the sacculus of a plurality of connections (accompanying drawing 2D), preferred this structure of sacculus that adopts a plurality of connections adopts this version the fore-end of sacculus can be inserted in the cervix uteri to obtain good slip-off preventing effect.
More specifically, described sacculus can be divided into large in little three specifications, large size: external diameter is not more than 8.5mm before the inflation, external diameter was not more than 11mm after fluid injection was expanded; Medium size: external diameter is not more than 7.5mm before the inflation, and external diameter was not more than 10mm after fluid injection was expanded; Small size: external diameter is not more than 6mm before the inflation, and external diameter was not more than 8.5mm after fluid injection was expanded.
Add the needs of part other medicines composition in order to satisfy in clinical use needs temporarily, can the sacculus liquid injection port be set stopping up the end of sacculus near uterine cavity, needed ingredient can be injected in the uterine cavity with liquid state by this sacculus liquid injection port.
Outer tube wall at double channel catheter is provided with the length mark graduation mark, and the doctor can confirm to stop up the position that sacculus 7 enters cervix uteri by the length graduation mark of sign in the use.
In order to monitor intrauterine pressure condition, the place arranges stress test interface 15 at the barrier carrier injection port, and piezometer 18 connects a hydraulic quick coupler 16 by stress test conduit 17, is connected with stress test interface 15 by hydraulic quick coupler 16 and carries out stress test.
Carrier barrier system of the present invention in use, by the treatment doctor harmless guiding bulb 5 logical vagina, the cervix uteri mouths that expanded of the suitable shape filling of cervix uteri dispensing device are entered in the uterine cavity, the doctor can confirm to stop up the position that sacculus 7 enters cervix uteri by the length graduation mark of double channel catheter 8 outer walls sign.Confirmed the correct position of obstruction sacculus as the doctor after, use needleless sacculus syringe 12 to inject medical saline by check valve 10 to stopping up in the sacculus, use the obstruction sacculus to be subjected to compression swelling, the cervix uteri collar extension is played ponding.
After confirming that the obstruction sacculus is reliable to the obstruction of cervix uteri mouth, rapid replacing interface 16 is connected to stress test end interface 15. opens valve 14, use the needleless medicine to penetrate device 13 and load the composite of composition (becoming to grade such as amnion cell, estrogen, anti-inflammatory drug composition and other cytoactives) by medicine injection port 6 in drug injection mouth 11, the uterine cavity to intrauterine injection carrier barrier material and/or other, the uterine cavity front and rear wall of adhesion is separated.Monitor simultaneously that in this process the demonstration pressure on the piezometer 18 is no more than 55mmHg (7.33KPa), inject compound colloid material and be no more than 6mL, after injection is finished, timely valve-off 14.
The piezometer of dismantling keeps this state after one period treatment time the suitable shape filling of cervix uteri dispensing device, and the taper injection port of needleless injector is inserted in the check valve, with the normal saline sucking-off of stopping up in the sacculus, and takes out package unit.
Although embodiment of the present invention has described disclosed system, corresponding component and mode of operation especially in detail; but be to be understood that; for those skilled in the art; many modifications are feasible; and in possible situation, corresponding flexible embodiment is regarded as and is met the description in claims fully or be within the scope that the present invention asks for protection.
Claims (7)
1. carrier barrier system that is applied to prevent and treat intrauterine adhesion, described carrier barrier system forms by the suitable type filling injection device of cervix uteri with as the carrier barrier material that is injected into, wherein, the suitable type filling of described cervix uteri injection device is by harmless guiding bulb, medicine injection port in the cervix uteri, stop up sacculus, double channel catheter, the barrier carrier injection port composition that is linked in sequence, position near the barrier carrier injection port on double channel catheter also is provided with sacculus injection bifurcations, the outer tube wall of double channel catheter is provided with the length mark graduation mark, the place is provided with valve at the barrier carrier injection port, the place is provided with check valve in sacculus injection bifurcations, it is characterized in that: be 5-9cm to the length of stopping up sacculus foremost from harmless guiding bulb, so that described obstruction sacculus places uterine cavity outside and clogging cervix uteri collar extension when harmless guiding bulb inserts uterine cavity; The material that the human body degradable that described carrier barrier material is colloid absorbs.
2. carrier barrier system as claimed in claim 1 is characterized in that: the carrier barrier material that wherein adopts is to be selected from a kind of in polylactic acid PLA polymeric material, polyglycolic acid PGA polymeric material, polycaprolactone (PCL), the fibrin gel.
3. carrier barrier system as claimed in claim 1, it is characterized in that: the place arranges the stress test end interface at the barrier carrier injection port, by hydraulic quick coupler Bonding pressure meter, the intrauterine pressure of filling in is monitored in real time.
4. carrier barrier system as claimed in claim 1, it is characterized in that: described obstruction sacculus adopts silica gel to make, the effective thickness of sacculus is 0.3-0.5mm, and maximum is withstand voltage to be 25Kpa, and its shape can be circular single saccule, the sacculus that is communicated with pair sacculus, capsule shape sacculus or a plurality of connections.
5. carrier barrier system as claimed in claim 4 is characterized in that: described obstruction sacculus be divided into large in little three specifications, three kinds of specifications are respectively: large size: external diameter is not more than 8.5mm before the inflation, external diameter was not more than 11mm after fluid injection was expanded; Medium size: external diameter is not more than 7.5mm before the inflation, and external diameter was not more than 10mm after fluid injection was expanded; Small size: external diameter is not more than 6mm before the inflation, and external diameter was not more than 8.5mm after fluid injection was expanded.
6. carrier barrier system as claimed in claim 4 is characterized in that: be provided with the sacculus liquid injection port at described obstruction sacculus near an end of uterine cavity.
7. carrier barrier system as claimed in claim 1 is characterized in that: also comprise carrier barrier syringe and sacculus syringe.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201220218130 CN202859206U (en) | 2012-05-16 | 2012-05-16 | Carrier barrier system applied to prevention and treatment of intrauterine adhesion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201220218130 CN202859206U (en) | 2012-05-16 | 2012-05-16 | Carrier barrier system applied to prevention and treatment of intrauterine adhesion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN202859206U true CN202859206U (en) | 2013-04-10 |
Family
ID=48025973
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201220218130 Expired - Lifetime CN202859206U (en) | 2012-05-16 | 2012-05-16 | Carrier barrier system applied to prevention and treatment of intrauterine adhesion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN202859206U (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102657546A (en) * | 2012-05-16 | 2012-09-12 | 段华 | Carrier barrier system applied to prevention and treatment of metrosynizesis |
| CN105769304A (en) * | 2014-12-22 | 2016-07-20 | 中国科学院沈阳自动化研究所 | Endoscopic surgery system aiming at endometrial repair and applications of endoscopic surgery system |
| CN106730259A (en) * | 2017-01-26 | 2017-05-31 | 中国人民解放军第三〇九医院 | A kind of bipartite uterus radiography water service pipe |
| CN113559051A (en) * | 2021-07-29 | 2021-10-29 | 北京赛升药业股份有限公司 | Injectable gelatin drug-loaded sustained-release system and preparation method thereof |
-
2012
- 2012-05-16 CN CN 201220218130 patent/CN202859206U/en not_active Expired - Lifetime
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102657546A (en) * | 2012-05-16 | 2012-09-12 | 段华 | Carrier barrier system applied to prevention and treatment of metrosynizesis |
| CN102657546B (en) * | 2012-05-16 | 2014-05-28 | 段华 | Carrier barrier system applied to prevention and treatment of metrosynizesis |
| CN105769304A (en) * | 2014-12-22 | 2016-07-20 | 中国科学院沈阳自动化研究所 | Endoscopic surgery system aiming at endometrial repair and applications of endoscopic surgery system |
| CN106730259A (en) * | 2017-01-26 | 2017-05-31 | 中国人民解放军第三〇九医院 | A kind of bipartite uterus radiography water service pipe |
| CN113559051A (en) * | 2021-07-29 | 2021-10-29 | 北京赛升药业股份有限公司 | Injectable gelatin drug-loaded sustained-release system and preparation method thereof |
| CN113559051B (en) * | 2021-07-29 | 2023-06-23 | 北京赛升药业股份有限公司 | Injectable gelatin drug-carrying slow-release system and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102657546B (en) | Carrier barrier system applied to prevention and treatment of metrosynizesis | |
| AU2007307639B2 (en) | Method and apparatus for occluding a lumen | |
| CN202776442U (en) | Packing device for treating uterine bleeding | |
| JPS5967969A (en) | Cathetel stayed in cervical canal | |
| CN202859206U (en) | Carrier barrier system applied to prevention and treatment of intrauterine adhesion | |
| CN103417272B (en) | A kind of medicine distribution type uterus support | |
| CN109350204A (en) | A kind of hemostatic bag for gynaecology | |
| CN202637025U (en) | Sacculus uterine support | |
| CN203468711U (en) | Multifunctional intrauterine adhesion control and treatment unit | |
| CN202859897U (en) | Cervical conformal packing and injecting device | |
| CN205612515U (en) | Be used for hemostatic device in uterus | |
| CN106108969A (en) | Hemostatic bag for gynaecology | |
| WO2020198504A1 (en) | Applications and imaging of shear-thinning biomaterial | |
| CN206508369U (en) | One uterine cryptomere support tube | |
| CN109513097A (en) | A kind of two-tube balloon-stent for preventing and treating Asherman's syndrom | |
| CN102657913A (en) | Cervical conformal packing injection device | |
| CN206630640U (en) | One kind hemostasis sacculus | |
| US20130150418A1 (en) | Apparatus and method for the treatment of abnormal uterine bleeding | |
| CN106552314B (en) | With analgesia delivery device after a kind of Asherman's syndrom exclusion | |
| CN115590654A (en) | Degradable implant for preventing intrauterine adhesion and preparation method thereof | |
| CN201775860U (en) | Double-cavity double-bag cervical dilatation tube | |
| CN204073050U (en) | Sacculus uterus support | |
| CN212756810U (en) | Disposable saccule uterine stent | |
| CN2160401Y (en) | Three-cavity one-bag anal canal | |
| CN205569008U (en) | Gynaecology and obstetrics's hemostasis bag |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CX01 | Expiry of patent term | ||
| CX01 | Expiry of patent term |
Granted publication date: 20130410 |